The new long-acting muscarinic antagonist and long-acting beta-agonist (LAMA/LABA) fixed dose combination (FDC) inhaler may be a better option than inhaled corticosteroids (ICS) for long-term use.

New users of LAMA-LABA therapy had a 20% reduction in the rate of first pneumonia hospitalization compared with new users of ICS-LABA (HR, 0.80; 95% CI, 0.75-0.86).

In this pair of trials, the LAMA component was tiotropium (Spiriva®), a 24-hour agent that has been available as a dry powder inhalation (HandiHaler®) for COPD for some years. The LABA component ...

In a cohort study, Feldman and colleagues analyzed 137,833 adults (mean age, 70.2 years; 50.4% women) from Optum’s Clinformatics Data Mart with COPD who were newly prescribed either LAMA-LABA ...

In smokers with COPD, LABA+LAMA is more effective than LABA+ICS in preventing exacerbations, regardless of blood eosinophil count.

Lung function was significantly improved with LAMA/LABA therapy compared with patients receiving preoperative LAMA therapy (FEV1, 223.1 mL vs. 130 mL; FEV 1 percent predicted, 10.8% vs. 6.8%).

Many medications can help relieve your COPD symptoms. ... LABA/LAMA as first-line therapy for COPD: A summary of the evidence and guideline recommendations. https: ...

The other single-inhaler on the market for COPD ... colleagues' study provides assurance to patients and clinicians when choosing a dry-powder inhaler over a metered-dose inhaler of LABA-LAMA ...

The researchers found that in patients with COPD, new LABA and LAMA use was associated with a 1.5- and 1.52-fold increased cardiovascular risk within 30 days of initiation, respectively; with ...

This includes two medications: LABA and LAMA bronchodilators. There are several fixed-dose LABA/LAMA combination inhalers available — these are inhalers that contain both medications in one.